These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. PRICE Investigators Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437 [TBL] [Abstract][Full Text] [Related]
43. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Serebruany VL; Kim MH; Cabrera-Fuentes HA; Lee K; Cho YR; Park K; Park TH; Kim YD; Yoon SC Thromb Haemost; 2017 May; 117(5):934-939. PubMed ID: 28251238 [TBL] [Abstract][Full Text] [Related]
44. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). Fosbøl EL; Ju C; Anstrom KJ; Zettler ME; Messenger JC; Waksman R; Effron MB; Baker BA; Cohen DJ; Peterson ED; Wang TY Circ Cardiovasc Interv; 2016 Nov; 9(11):. PubMed ID: 27789517 [TBL] [Abstract][Full Text] [Related]
45. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
46. Cardiac Rehabilitation Participation and Mortality After Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Beatty AL; Doll JA; Schopfer DW; Maynard C; Plomondon ME; Shen H; Whooley MA J Am Heart Assoc; 2018 Oct; 7(19):e010010. PubMed ID: 30371315 [TBL] [Abstract][Full Text] [Related]
48. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271 [TBL] [Abstract][Full Text] [Related]
49. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425 [TBL] [Abstract][Full Text] [Related]
50. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860 [TBL] [Abstract][Full Text] [Related]
51. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry. Safley DM; Venkitachalam L; Kennedy KF; Cohen DJ JACC Cardiovasc Interv; 2015 Oct; 8(12):1574-82. PubMed ID: 26493250 [TBL] [Abstract][Full Text] [Related]
52. Impact of Access Site Practice on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Thrombolysis for ST-Segment Elevation Myocardial Infarction in the United Kingdom: An Insight From the British Cardiovascular Intervention Society Dataset. Rashid M; Rushton CA; Kwok CS; Kinnaird T; Kontopantelis E; Olier I; Ludman P; De Belder MA; Nolan J; Mamas MA JACC Cardiovasc Interv; 2017 Nov; 10(22):2258-2265. PubMed ID: 29169494 [TBL] [Abstract][Full Text] [Related]
53. Facility-Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program. Bradley SM; O'Donnell CI; Grunwald GK; Liu CF; Hebert PL; Maddox TM; Jesse RL; Fihn SD; Rumsfeld JS; Ho PM Circulation; 2015 Jul; 132(2):101-8. PubMed ID: 25951833 [TBL] [Abstract][Full Text] [Related]
54. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007 [TBL] [Abstract][Full Text] [Related]
55. Temporal Trends in Coronary Angiography and Percutaneous Coronary Intervention: Insights From the VA Clinical Assessment, Reporting, and Tracking Program. Waldo SW; Gokhale M; O'Donnell CI; Plomondon ME; Valle JA; Armstrong EJ; Schofield R; Fihn SD; Maddox TM JACC Cardiovasc Interv; 2018 May; 11(9):879-888. PubMed ID: 29747919 [TBL] [Abstract][Full Text] [Related]
56. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243 [TBL] [Abstract][Full Text] [Related]